LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics-Reference-Cited by-同舟云学术

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics

Published:2017-02-03 Issue:6 Volume:77 Page:654-671
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Nguyen Holly M.¹,Vessella Robert L.¹²,Morrissey Colm¹,Brown Lisha G.¹,Coleman Ilsa M.³,Higano Celestia S.⁴⁵,Mostaghel Elahe A.⁴,Zhang Xiaotun¹,True Lawrence D.⁶,Lam Hung-Ming¹,Roudier Martine¹,Lange Paul H.¹,Nelson Peter S.¹³⁶,Corey Eva¹

Affiliation:

1. Department of Urology; University of Washington; Seattle Washington

2. Puget Sound Veteran Administration; Seattle Washington

3. Division of Human Biology; Fred Hutchinson Cancer Research Center; Seattle Washington

4. Division of Clinical Research; Fred Hutchinson Cancer Research Center; Seattle Washington

5. Division of Oncology; Department of Medicine; University of Washington; Seattle Washington

6. Department of Pathology; University of Washington; Seattle Washington

Funder

Richard M. Lucas Foundation

Prostate Cancer Foundation

NIH

PNW Prostate Cancer SPORE NIH

Department of Defense Prostate Cancer Research Program

FHCRC/UW Cancer Consortium

Institute of Prostate Cancer Research

a Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research

Publisher

Wiley

Subject

Urology,Oncology

Reference48 articles.

1. CECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer;Sweeney;Clin Adv Hematol Oncol,2006

2. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven;Attard;Cancer Res,2009

3. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer;Attard;J Clin Endocrinol Metab,2012

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

2. Computational Analysis of Treatment Resistant Cancer Cells;2024-08-31

3. Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines;2024-08-30

4. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers;Cell Death & Disease;2024-08-25

5. Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer;Nature Communications;2024-08-06